轴性脊柱关节炎治疗市场 - 2017-2027年全球行业规模、份额、趋势、机会和预测，按疗法、按适应症、按终端用户、按公司和按地区划分

全球轴性脊柱关节炎治疗市场预计将在2023-2027年预测期内观察到令人瞩目的增长。主要因素包括轴性脊柱关节炎发病率的上升和公众对该疾病认识的提高，都推动了市场的增长。轴性脊柱关节炎是一种影响轴性骨骼的慢性炎症性疾病。患者会因此而经历严重的不适，背部僵硬，以及疲劳。支持市场增长的其他因素有：世界人口增长、研究活动增加、病人数量激增、大量临床试验、产品创新和开发增加、对研究和开发的大量投资、人均医疗保健支出增加、轴突性关节炎患病率增加、合併和收购数量增加，以及一些当局对改善现有医疗保健基础设施的重视。

轴性脊柱关节炎发病率的激增

全球范围内轴性脊柱关节炎发病率的增加正在推动市场的增长。轴性脊柱关节炎的病因尚不清楚，但经过多次研究，人们认为它是由于基因暴露于某些细菌、病毒或其他触发因素而引起的。患者会经历严重的不适，如受影响部位的僵硬和疲劳。不仅是老年人群，年轻一代也很容易患上这种疾病。因此，这些因素正在推动全球市场的增长。根据一项引用的研究，在美国，大约有270万美国人或更多的人受到轴突性关节炎（axSpA）的影响。

获得批准的生物仿制药的数量增加

根据世界卫生组织（WHO），生物仿制药是指在安全、质量和疗效方面与已经获得许可的原始生物治疗产品相似的生物治疗产品。生物仿制药是有助于治疗轴性脊柱关节炎等疾病的生物药物。它们对病人非常有效，由于其更容易获得，已经取代了原研药。在过去的几年里，获准用于治疗轴性脊柱关节炎的生物仿制药数量激增，这正在促进全球市场的增长。例如，在2020年和2021年，美国食品和药物管理局批准了三种新型产品，即Xeljanz、Taltz和Cosentyx，以治疗轴突性关节炎患者。

不断增加的研发活动

分子和免疫学领域的研究和开发（R&D）活动的增加正在推动市场的增长。由于研究活动的增加，新型生物制剂的出现，如肿瘤坏死因子（TNF）抑制剂、IL-23和白细胞介素（IL）-17抑制剂正在猛增。例如，2022年，全球生物制药公司UCB宣布了积极的顶线中期分析结果，显示3期BE MOBILE 1研究达到了主要和所有排名第二的终点。BE MOBILE 1是衡量bimekizumab在患有活动性非放射状轴性关节炎（nr-axSpA）的成人中的有效性和安全性的主要研究。此外，政府对研究活动的投资增加也促进了市场的增长。

可用的定制服务

利用给定的市场数据，TechSci Research根据公司的具体需求提供定制服务。该报告有以下定制选项：

公司信息

• 其他市场参与者（最多5家）的详细分析和简介。

目录

第一章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19对全球轴性脊柱关节炎治疗市场的影响

第五章：客户的声音

第六章：临床试验分析

第七章 ：全球轴突性脊柱关节炎治疗市场展望

• 市场规模和预测
  • 按价值
• 市场份额与预测
  • 按疗法分类（抗肿瘤坏死因子（TNF）疗法、抗白细胞介素（IL）疗法、抗雅努斯激酶（JAK）疗法）
  • 按适应症（强直性脊柱炎和/或非放射型轴索性脊柱关节炎治疗）
  • 按终端用户（医院和诊所、学术和研究机构、其他）分类
  • 按地区
  • 按公司分类(2021年)
• 市场地图

第八章：北美轴突性脊柱关节炎治疗市场展望

• 市场规模和预测
  • 按价值
• 市场份额与预测
  • 按疗法分类
  • 按适应症分类
  • 按终端用户分类
  • 按国家分类
• 北美洲：国家分析
  • 美国
  • 美国
  • 墨西哥

第九章：欧洲轴突性脊柱关节炎治疗市场前景

• 市场规模和预测
  • 按价值
• 市场份额与预测
  • 按疗法分类
  • 按适应症分类
  • 按终端用户分类
  • 按国家分类
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第十章：亚太地区轴性脊柱关节炎治疗市场前景

• 市场规模和预测
  • 按价值
• 市场份额与预测
  • 按疗法分类
  • 按适应症分类
  • 按终端用户分类
  • 按国家分类
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳大利亚

第11章 ：南美轴性脊柱关节炎治疗市场展望

• 市场规模和预测
  • 按价值计算
• 市场份额与预测
  • 按疗法分类
  • 按适应症分类
  • 按终端用户分类
  • 按国家分类
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十二章 ：中东和非洲轴性脊柱关节炎治疗市场展望

• 市场规模和预测
  • 按价值
• 市场份额和预测
  • 按疗法分类
  • 按适应症分类
  • 按终端用户分类
  • 按国家分类
• MEA: 国家分析
  • 南非轴突性脊柱关节炎的治疗
  • 沙特阿拉伯轴突性脊柱关节炎的治疗
  • 阿联酋轴突性脊柱关节炎的治疗

第十三章 ：市场动态

• 驱动力
• 挑战

第十四章：市场趋势与发展

第十五章 ：竞争格局(包括SWOT分析)

• 诺华国际公司（Novartis International, AG
• 礼来公司
• 强生公司
• UCB S.A.
• 辉瑞公司（Pfizer, Inc.
• 京华麒麟股份有限公司
• 默克公司（Merck & Co.
• 艾伯维公司
• Bristol-Myers Squibb公司
• FunPep有限公司

第16章 ：战略建议

The global axial spondyloarthritis treatment market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of axial spondyloarthritis and increasing public awareness of the disease, are propelling the growth of the market. Axial spondyloarthritis is a chronic inflammatory condition that impacts the axial skeleton. The person undergoes severe discomfort, stiffness in the back area, and fatigue because of it. The other factors supporting the market's growth are the growing world population, increasing research activities, a surge in the number of patients, a large number of clinical trials, rising product innovation and development, significant investment in research and development, rising per capita health care expenditure, increasing prevalence of axial spondyloarthritis, growing number of mergers and acquisitions, and rising emphasis of several authorities on improving existing healthcare infrastructure.

A surge in Incidences of Axial Spondylarthritis

The increasing prevalence of axial spondylarthritis across the globe is bolstering the growth of the market. The cause of axial spondylarthritis is not known, but after several research, it is assumed that it is caused due to the exposure of genes to certain bacteria, viruses, or other triggers. Patients undergo serious discomforts, such as stiffness in the affected part and fatigue. Not only the elderly population but the younger generation are also prone to the disease. Therefore, these factors are bolstering the growth of the market globally. According to a cited study, in the U.S., about 2.7 million Americans or more are affected by axial spondyloarthritis (axSpA).

Increase in the Number of Approved Biosimilars

According to the World Health Organization (WHO), Biosimilars refer to a biotherapeutic product that is similar in terms of safety, quality, and efficacy to an already licensed original biotherapeutic product. Biosimilars are biological drugs that help in treating diseases such as axial spondylarthritis. They are very effective in patients and have replaced originator drugs due to their greater accessibility. In the past few years, there has been a surge in the number of approved biosimilars for the treatment of axial spondylarthritis, which is augmenting the growth of the market globally. For instance, in 2020 and 2021, the U.S. Food and Drug Administration approved three novel products, i.e., Xeljanz, Taltz, and Cosentyx, to treat individuals with axial spondyloarthritis.

Increasing R&D Activities

Rise in research and development (R&D) activities in the molecular and immunologic field are propelling the growth of the market. Owing to the increase in research activities, the advent of novel biologic agents such as tumor necrosis factor (TNF) inhibitors, IL-23, and interleukin (IL)-17 inhibitors are surging. For instance, in 2022, UCB, a global biopharmaceutical company, announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the primary study to measure the effectiveness and safety of bimekizumab in adults suffering from active non-radiographic axial spondyloarthritis (nr-axSpA). Moreover, the rising investments in the research activities by the government are facilitating the growth of the market.

Market Segmentation

The global axial spondyloarthritis treatment market is segmented into therapy, indication, end user, and company. Based on therapy, the market is divided into anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) therapy, and anti-Janus kinase (JAK) therapy. Based on indication, the market is divided into ankylosing spondylitis and non-radiographic axial spondyloarthritis treatment. Based on end-user, the market is divided into hospitals & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rise in R&D activities in the country.

Market Players

Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd. are some of the leading companies operating in the market.

Report Scope

In this report, global axial spondyloarthritis treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Axial Spondyloarthritis Treatment Market, By Therapy:

• Anti-Tumor Necrosis Factor (TNF) Therapy
• Anti-Interleukin (IL) Therapy
• Anti-Janus Kinase (JAK) Therapy

Axial Spondyloarthritis Treatment Market, By Indication:

• Ankylosing Spondylitis
• Non-radiographic Axial Spondyloarthritis Treatment

Axial Spondyloarthritis Treatment Market, By End User:

• Hospitals & Clinics
• Academic & Research Institutions
• Others

Axial Spondyloarthritis Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Europe & CIS
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Axial Spondyloarthritis Treatment Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Axial Spondyloarthritis Treatment Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Axial Spondyloarthritis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy)
  • 7.2.2. By Indication (Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis Treatment)
  • 7.2.3. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)
  • 7.2.4. By Region
  • 7.2.5. By Company (2021)
• 7.3. Market Map

8. North America Axial Spondyloarthritis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Axial Spondyloarthritis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. Canada Axial Spondyloarthritis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Mexico Axial Spondyloarthritis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User

9. Europe Axial Spondyloarthritis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Europe: Country Analysis
  • 9.3.1. France Axial Spondyloarthritis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. Germany Axial Spondyloarthritis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. United Kingdom Axial Spondyloarthritis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User
  • 9.3.4. Italy Axial Spondyloarthritis Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Therapy
      • 9.3.4.2.2. By Indication
      • 9.3.4.2.3. By End User
  • 9.3.5. Spain Axial Spondyloarthritis Treatment Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Therapy
      • 9.3.5.2.2. By Indication
      • 9.3.5.2.3. By End User

10. Asia-Pacific Axial Spondyloarthritis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. Asia-Pacific: Country Analysis
  • 10.3.1. China Axial Spondyloarthritis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. India Axial Spondyloarthritis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Japan Axial Spondyloarthritis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User
  • 10.3.4. South Korea Axial Spondyloarthritis Treatment Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Therapy
      • 10.3.4.2.2. By Indication
      • 10.3.4.2.3. By End User
  • 10.3.5. Australia Axial Spondyloarthritis Treatment Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Therapy
      • 10.3.5.2.2. By Indication
      • 10.3.5.2.3. By End User

11. South America Axial Spondyloarthritis Treatment Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Therapy
  • 11.2.2. By Indication
  • 11.2.3. By End User
  • 11.2.4. By Country
• 11.3. South America: Country Analysis
  • 11.3.1. Brazil Axial Spondyloarthritis Treatment Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Therapy
      • 11.3.1.2.2. By Indication
      • 11.3.1.2.3. By End User
  • 11.3.2. Argentina Axial Spondyloarthritis Treatment Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Therapy
      • 11.3.2.2.2. By Indication
      • 11.3.2.2.3. By End User
  • 11.3.3. Colombia Axial Spondyloarthritis Treatment Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Therapy
      • 11.3.3.2.2. By Indication
      • 11.3.3.2.3. By End User

12. Middle East and Africa Axial Spondyloarthritis Treatment Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Therapy
  • 12.2.2. By Indication
  • 12.2.3. By End User
  • 12.2.4. By Country
• 12.3. MEA: Country Analysis
  • 12.3.1. South Africa Axial Spondyloarthritis Treatment Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Therapy
      • 12.3.1.2.2. By Indication
      • 12.3.1.2.3. By End User
  • 12.3.2. Saudi Arabia Axial Spondyloarthritis Treatment Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Therapy
      • 12.3.2.2.2. By Indication
      • 12.3.2.2.3. By End User
  • 12.3.3. UAE Axial Spondyloarthritis Treatment Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Therapy
      • 12.3.3.2.2. By Indication
      • 12.3.3.2.3. By End User

13. Market Dynamics

• 13.1. Drivers
• 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape (Inclusive SWOT Analysis)

• 15.1. Novartis International, AG
• 15.2. Eli Lilly and Company
• 15.3. Johnson & Johnson
• 15.4. UCB S.A.
• 15.5. Pfizer, Inc.
• 15.6. Kyowa Kirin Co., Ltd.
• 15.7. Merck & Co., Inc.
• 15.8. AbbVie Inc
• 15.9. Bristol-Myers Squibb Company
• 15.10. FunPep Co., Ltd.

16. Strategic Recommendations